Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing restorative treatments for neuropsychiatric and neuroimmunologic disorders. Their pipeline is led by ABX-002, a thyroid hormone receptor beta agonist for depression, and ABX-101, an S1P receptor modulator for neuroimmunologic disorders. The company leverages a brain-targeting chemistry platform to enhance drug concentrations in the brain for improved efficacy.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $100M
Date: 24-Jul-2024
Investors: Newpath Partners, Canaan Partners, Monograph Capital, Insight Partners, ARCH Venture Partners, Blue Owl Healthcare Opportunities, BVF Partners, Invus, Samsara BioCapital, Biogen, Bristol Myers Squibb, Pfizer Ventures, Section 32, Alexandria Venture Investments, GT Healthcare Capital Partners
Markets: Biotechnology, Pharmaceuticals, Neuropsychiatry, Neuroimmunology
HQ: San Diego, California, United States
Founded: 2017
Website: https://www.autobahntx.com
LinkedIn: https://www.linkedin.com/company/autobahn-therapeutics-inc
Crunchbase: https://www.crunchbase.com/organization/autobahn-therapeutics
Leave a Comment
Comments
No comments yet.